Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Stock Information for Veru Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Veru Inc.

Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
Veru to Report Fiscal Year 2025 Financial Results on December 17th
Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop
Veru to Present Two Abstracts at ObesityWeek 2025
Veru Announces Proposed Public Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.